Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)

CAPS Rating: 2 out of 5

The Company is engaged in the discovery and development of breakthrough medicines to treat cancers by regulating cell signaling with small molecules.

Recs

0
Player Avatar polterziets (< 20) Submitted: 6/4/2011 5:51:01 PM : Outperform Start Price: $7.90 ARIA Score: +109.39

growth and very undervalued

Report this Post Reply

Featured Broker Partners


Advertisement